This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Harvard dodges abuse-of-rights claim by Vizgen at UPC, announces US settlement

By Inbar Preiss and Melissa Ritti ( February 7, 2025, 13:38 GMT | Insight) -- A hearing next week at the Court of Appeal for the Unified Patent Court is off, following the announcement yesterday that Harvard University and 10x Genomics settled their patent dispute with Vizgen mid-trial in the US. A UPC first instance court, in two orders last fall, directed the production of e-mails gleaned in that US litigation, which Vizgen said would show Harvard and 10x employed a "copy-acquire-kill" and "open early, closed late" strategy to force competitors out of the single-cell spatial transcriptomics market. Now, those allegations will go unargued.Vizgen appears to be on the verge of a global settlement with the President and Fellows of Harvard College and biotech developer 10x Genomics Inc....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections